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Early menopause (EM) affects up to 10% of the female population, reducing reproductive lifespan considerably.
Currently, it constitutes the leading cause of infertility in the western world, affecting mainly those women who
postpone their ﬁrst pregnancy beyond the age of 30 years. The genetic aetiology of EM is largely unknown in
the majority of cases. We have undertaken a meta-analysis of genome-wide association studies (GWASs) in
3493 EM cases and 13598 controls from 10 independent studies. No novel genetic variants were discovered,
but the 17 variants previously associated with normal age at natural menopause as a quantitative trait (QT)
were also associated with EM and primary ovarian insufﬁciency (POI). Thus, EM has a genetic aetiology
which overlaps variation in normal age at menopause and is at least partly explained by the additive effects
of the same polygenic variants. The combined effect of the common variants captured by the single nucleotide
polymorphism arrays was estimated to account for ∼30% of the variance in EM. The association between the
combined 17 variants and the risk of EM was greater than the best validated non-genetic risk factor, smoking.
INTRODUCTION
Menopause represents a major hormonal change, characterized
by a decline in oestrogen and progesterone levels and cessa-
tion of female reproductive function as the ovarian reserve
is exhausted (1). It inﬂuences a woman’s well-being and
early menopause (EM) is associated with increased risk of
age-related diseases including cardiovascular disease, osteo-
arthritis and osteoporosis, but reduced risk of breast cancer (2).
The average age at natural menopause in women of North-
ern European descent is 50 to 51 years (3,4). Early entry into
menopause has implications for women’s fertility. Fertility
starts to decrease on average at about age 30 years and is con-
siderably diminished after age 35. It is estimated that natural
fecundity ceases at a mean age of 41 years, i.e. 10 years
before menopause (5). In recent decades, the average age at
which a woman gives birth to her ﬁrst child has increased
from around 25 up to 30 years of age (6). As a consequence,
women who are at risk of EM and who delay childbearing
until their 30’s are more likely to have problems conceiving
(2). This tendency has led to an increase in age-related infer-
tility, subsequently increasing the utilization of assisted
reproductive technologies (ARTs). Better understanding of
the mechanisms that lead to EM, and even the ability to
predict it, could greatly improve family planning and reduce
the need for invasive and costly ART treatments (5,7).
Heritability estimates for age at natural menopause, from
twin and family studies, range from 44–65%, suggesting a
substantial genetic component to the trait (8–12). Initial
genome-wide association studies (GWASs) identiﬁed 4 loci
associated with variation in age at natural menopause in the
normal range (40–60 years) (13,14) and more recent
GWASs have added a further 13 loci, bringing the total to
17, including genes implicated in DNA repair and immune
function (15). The effect size ranged from 8.7 weeks to
nearly 1 year (50.5 weeks) per allele and the 17 single nucleo-
tide polymorphisms (SNPs) together explained 2.5–4.1% of
the population variation in natural menopausal age.
EM, deﬁned as menopause occurring before 45 years of age,
occurs in  5–10% of women and primary ovarian insufﬁ-
ciency (POI) when menstruation ceases before 40 years,
affects  1% of women (3,16,17). Premature ovarian ageing
may be the consequence of a precocious decline of the prim-
ordial follicle pool, which is established during fetal life,
1466 Human Molecular Genetics, 2013, Vol. 22, No. 7leading to a loss of negative feedback from ovarian sex ster-
oids and inhibins on the hypothalamic–pituitary axis.
Oocyte quality decreases with increasing age and EM may
reﬂect the damage accumulated during reproductive life,
and/or age-related changes in granulosa cell–oocyte commu-
nication (18). EM may be caused by genetic defects (eg.
Turner syndrome or FMR1 premutations), autoimmunity or
iatrogenic (as a consequence of surgery, chemotherapy or ra-
diation) or might be the consequence of environmental
factors. Unexplained EM also has a substantial genetic compo-
nent (19). A woman whose mother had an EM has  6-fold
increased risk of having EM (8,20). However, in the majority
of cases, the genes involved in EM are largely unknown and
may be different from the genes regulating age at menopause
in the normal range.
We have addressed this issue by conducting a GWAS com-
paring EM cases with controls who had menopause at ages
50–60 years, in the ReproGen consortium. We ﬁnd consider-
able overlap between the genetic variation that contributes to
normal menopause age and EM.
RESULTS
To identify common genetic variants associated with EM, we
followed a two-stage, case–control approach. From the Repro-
Gen consortium cohorts with GWAS data, we selected cases
as women with age at menopause before 45 years (N ¼ 3493)
and controls as women with age at menopause between 50 and
60 years (N ¼ 13598). Only cohorts with ≥100 cases were
included,giving10independentstudies(SupplementaryMater-
ial, Table S1). Meta-analysis of this EM discovery dataset iden-
tiﬁed four independent signals with P-values stronger than the
genome-wide signiﬁcant threshold of P , 5 × 10
28 (Supple-
mentaryMaterial, TableS2).Allthefoursignalshadbeeniden-
tiﬁed in the ReproGen quantitative trait (QT) GWAS of normal
menopause age (15). A further four SNPs were borderline sig-
niﬁcant for EM (P , 5 × 10
27, Supplementary Material,
Table S2) and two of these had not been previously identiﬁed
in the QT GWAS: rs1867631 in SGIP1 at chromosome 1p31.3
and rs1473307 near NYAP2 at chromosome 2q36.3. Both
SNPs were carried forward for replication by de novo genotyp-
ing or in silico analyses in an additional sample of 3412 cases
and 4928 controls, from four cohorts (Supplementary Material,
Table S1). For both SNPs the association P-value increased
whenthereplicationdatawerecombinedwiththeEMdiscovery
data(SupplementaryMaterial,TableS3);thus,wefoundnoevi-
dence for novel genetic loci associated with EM.
To estimate the proportion of variance explained by all
common variants captured on the SNP arrays in a polygenic
model, we used genome-wide complex trait analysis (analysis
tools available at: http://www.complextraitgenomics.com/
software/gcta/). We estimated the variance explained in
the WGHS cohort, one of the largest cohorts used in the
meta-analysis (N ¼ 10 302). For menopause as a QT, the
SNPs explain 21% of the variance (P ¼ 1 × 10
211,s e ¼
0.03) in a model taking residuals of menopause age with
body mass index, smoking and population eigenvectors.
Using the same approach and assuming a population
prevalence of 5 or 10%, heritability of EM due to the SNP
array genotypes was estimated to be 27 and 33%, respectively
(P ¼ 0.006, se ¼ 0.11; P ¼ 0.006, se ¼ 0.13, respectively).
To identify associations at the gene level, where combina-
tions of multiple SNPs may contribute in aggregate, we ran
the Versatile Gene-Based Association Study’ (VEGAS) test.
Using our full discovery meta-analysis, VEGAS produced
gene-level results for 17 580 genes. No genes passed our con-
servative Bonferroni correction at the 0.05 level (P ¼ 2.8 ×
10
26). There were 48 genes with P , 0.001 from the
VEGAS analysis, we used GRAIL to identify any of these
48 genes which shared functional links with any gene within
the 17 known menopause regions. Four genes reached a
GRAIL P , 0.05; MCM6 (most similar to MCM8, top SNP
rs2164210—P ¼ 7 × 10
25), C6orf150 (similar to SYCP2L,
top SNP rs311686—P ¼ 7 × 10
24), CRHR1 (similar to
UCN, top SNP rs4640231—P ¼ 2 × 10
24), SLC25A13
(similar to POLG, top SNP rs2375044—P ¼ 2 × 10
25).
Pathway analysis with Magenta revealed no signiﬁcant enrich-
ment of biological pathways in EM.
The role of loci associated with variation in normal age at
menopause in women with early menopause and POI
We next investigated the risk of EM for each of the 17 variants
that were associated with normal variation in menopause age
reported in the ReproGen QT GWAS. In silico data were
available for 3840 individuals with EM (those with age at
menopause 40–44 years were included in the previous QT
GWAS
15, individuals with age at menopause ,40 years
have not been included previously). A further 1365 cases
and 2475 controls from three studies not included in that QT
GWAS were directly genotyped or had in silico data for the
17 SNPs. The odds ratios (ORs) for EM were in the same dir-
ection and of a similar magnitude in the discovery EM GWAS
and in the meta-analysis of the three additional independent
cohorts (Supplementary Material, Table S4). Combining
both datasets, all 17 QT GWAS SNPs were nominally asso-
ciated with EM (P-value ,0.05) and were all directionally
consistent with their effects on normal age at menopause
(Table 1 and Supplementary Material, Table S4). The SNPs
with the largest association with age at menopause in the
normal range had the greatest OR for EM (Fig. 1).
In ﬁve of the studies (two from the discovery EM GWAS and
threeoftheadditionalindependentstudies),thereweremorethan
100individualswithmenopausebefore40years(Supplementary
Material, Table S1). We tested the association of the 17 meno-
pause SNPs in 1108 POI cases and 7727 controls who were not
part of the sample for the QT GWAS. Despite limited power
from the relatively small sample size, rs11668344 on chromo-
some 19 was signiﬁcantly associated with POI in the
meta-analysis [OR ¼ 1.30 (CI 1.21–1.47), P ¼ 5.39 × 10
28;
after Bonferroni correction accounting for 17 tests]. Of the
remaining 16 SNPs, all had an effect in the expected direction
and eight were nominally associated with POI (P , 0.05)
(Table 1). We also explored associations with EM and POI
using dominantand recessivemodels for eachthe 17 menopause
variants and found no evidence for any SNP acting in a non-
additive fashion (Supplementary Material, Table S5).
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Table 1. Effect of 17 SNPs, identiﬁed by the GWAS of normal menopause QT, in EM and POI cases versus controls
SNPID Chr Location
(bp)
Effect allele Effect allele
frequency
Normal menopause QT GWAS EM cases versus controls POI cases versus controls
Effect (years) SE P-value OR [95% CI] P-value Dir OR [95% CI] P-value Dir
rs16991615 20 5896227 g 0.93 20.948 0.052 1.4E 2 73 1.55 [1.41–1.71] 5.8E 2 20 22222 1.17 [0.99–1.39] 0.07 2222+
rs11668344 19 60525476 g 0.36 20.416 0.026 1.5E 2 59 1.33 [1.27–1.4] 2.2E 2 32 ? 2222 1.34 [1.21–1.47] 3.7E 2 09 2? 222
rs2517388 8 38096889 t 0.83 20.262 0.034 9.3E 2 16 1.23 [1.15–1.32] 1.5E 2 09 ? 2 +++ 1.22 [1.05–1.41] 0.008 + ? 2 + 2
rs2277339 12 55432336 g 0.1 20.38 0.042 2.5E 2 19 1.19 [1.1–1.28] 5.8E 2 06 ? 2222 1.21 [1.04–1.4] 0.01 2? 222
rs12294104 11 30339475 c 0.83 20.225 0.033 1.5E 2 11 1.18 [1.11–1.26] 2.2E 2 07 ? 2222 1.21 [1.07–1.38] 0.004 2? 222
rs1046089 6 31710946 a 0.35 20.213 0.026 1.6E 2 16 1.16 [1.11–1.22] 9.2E 2 10 ? 22++ 1.16 [1.05–1.28] 0.003 + ? 2 ++
rs12461110 19 61012475 a 0.36 20.158 0.026 8.7E 2 10 1.16 [1.1–1.21] 4.0E 2 09 ? ++++ 1.14 [1.03–1.26] 0.01 + ? +++
rs4246511 1 39152972 c 0.73 20.24 0.029 9.0E 2 17 1.14 [1.08–1.21] 1.2E 2 06 ? + 222 1.08 [0.97–1.2] 0.15 2 ? + 2 +
rs4886238 13 60011740 g 0.67 20.17 0.026 9.5E 2 11 1.14 [1.08–1.2] 2.5E 2 07 ? 2222 1.2 [1.08–1.33] 0.0006 2? 222
rs10852344 16 11924420 t 0.58 20.168 0.025 1.0E 2 11 1.13 [1.08–1.19] 2.0E 2 07 ? 2+++ 1.03 [0.93–1.13] 0.60 2? 2 ++
rs10183486 2 1.72E+08 t 0.37 20.196 0.026 2.2E 2 12 1.13 [1.08–1.19] 3.6E 2 07 ? ++++ 1.12 [1.02–1.23] 0.02 + ? ++2
rs2153157 6 11005474 g 0.51 20.165 0.024 7.8E 2 12 1.12 [1.07–1.18] 6.2E 2 07 ? 2222 1.10 [1.0–1.21] 0.06 2? 2 + 2
rs2303369 2 27568920 t 0.39 20.175 0.025 2.3E 2 12 1.12 [1.07–1.18] 1.1E 2 06 ? 2 +++ 1.09 [0.99–1.2] 0.09 +? 2 ++
rs2307449 15 87664932 g 0.4 20.184 0.025 3.6E 2 13 1.12 [1.07–1.17] 3.0E 2 06 ? + 222 1.18 [1.07–1.3] 0.0009 2 ? + 22
rs365132 5 1.76E+08 g 0.51 20.287 0.025 9.1E 2 32 1.11 [1.06–1.16] 1.1E 2 05 ? + 222 1.05 [0.96–1.16] 0.27 + ? 222
rs1635501 1 2.4E+08 c 0.48 20.164 0.027 8.5E 2 10 1.1 [1.05–1.16] 0.0002 ? 2222 1.04 [0.94–1.14] 0.45 2 ? + 2 +
rs4693089 4 84592646 a 0.51 20.228 0.025 2.4E 2 19 1.09 [1.04–1.14] 0.0005 ? 2 +++ 1.04 [0.94–1.14] 0.45 + ? 2 ++
SNPs are ordered by OR for EM. Direction of effects for individual studies given in the following order: BGS, Colaus, EGCUT, NIDO, discovery for EM and Aric, BGS, Colaus, NIDO, WGHS for POI. ?
indicates that a study did not contribute data for that SNP, either because not genotyped or failed QC.
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7P ¼ 7.75 × 10
210) was observed in the NIDO cohort,
which was similar to the estimate in EGCUT (OR ¼ 1.14
([CI 1.08–1.19], P ¼ 6 × 10
28).
We divided the case–control samples into risk quintiles,
based on the number of risk alleles they carried, weighted by
the relative effect sizes of those alleles from the EM
discovery + replication GWAS meta-analysis. The risk of
EM associated with being in each quintile relative to the
median quintile is shown in Figure 2. An OR of 2.47([CI
1.94–3.14], P ¼ 2.7 × 10
213) for EM risk was observed
when comparing the top 20%, with the most EM risk alleles,
with the bottom 20%. This difference was higher when com-
bined with smoking status. The smoking status alone (current
versus former/never smokers) was associated with a doubling
in risk for EM (OR 1.96 [CI 1.51–2.56], P ¼ 6 × 10
27).
Those women with the combination of the top 20% EM risk
allele group plus current smoking had an OR of 3.38 ([CI
1.74–6.59], P ¼ 0.003) higher risk of EM than those in the
lowest 20% EM risk allele group who were former/never
smokers.
We tested the ability of the 17 SNPs to discriminate EM
cases from controls by calculating a receiver operating charac-
teristic (ROC) area under the curve (AUC), using individual’s
weighted EM risk allele score and smoking status. Data from
the NIDO and EGCUT cohorts gave highly concordant results,
with an AUC of 0.60 for the 17 SNPs. This showed a signiﬁ-
cant improvement over smoking status alone (AUC ¼ 0.55).
Combining genetic and smoking risk factors gave an AUC
of 0.63 (sensitivity ¼ 35.4%, speciﬁcity ¼ 81.3%).
Prior to the recent identiﬁcation of 13 new variants asso-
ciated with normal age at menopause, there were four loci
reported, which were replicated in the more recent study,
(13,14, 15). The AUC for the ﬁrst four published loci asso-
ciated with age at menopause was 0.55.
DISCUSSION
Shared aetiology of EM/POI and normal menopause
A recent GWAS has identiﬁed 17 loci associated with age at
natural menopause in the normal range (40–60 years),
explaining  4% of the variation in menopause age (15).
However, this GWAS excluded women who had menopause
before 40 years (POI), a condition affecting  1% of the
female population. EM leads to short reproductive lifespan
and is also associated with several harmful health outcomes in-
cluding increased risk of cardiovascular diseases (21). Up to
30% of POI cases have an affected relative suggesting a sub-
stantial genetic burden in these women, but candidate gene
studies have been unable to determine a genetic cause in the
majority of cases (22). The deﬁnition of POI is arbitrarily
based on the population distribution of menopause age,
affected women representing the extreme 1% tail ( 2.5 SDs
from the mean), rather than distinct clinical characteristics.
A small proportion of women with POI spontaneously con-
ceive and thus, it is a heterogeneous condition. We hypothe-
sized that very EM has distinct genetic aetiology compared
with menopause age within the normal range, caused by
either independent deleterious variants in the known age at
menopause genes, or by variants at different loci, which
have a larger effect on menopause age. In order to under-
stand the genetic aetiology of menopause at the extreme of
the age distribution, we performed a GWAS in women
with menopause before 45 years of age. This ensured that
we captured the full spectrum of ovarian insufﬁciency and
gave us a large enough sample size to make it feasible to
perform a GWAS; however, a clinical diagnosis of POI
was not recorded in any of our studies. It is also possible
that rare variants, poorly captured by the SNP chips, are
Figure 2. Distribution of the age at menopause-lowering allele score (quintiles) in women with EM and controls and ORs (95% CIs) for EM. Data shown are
from the two replication cohorts combined. OR’s are calculated relative to the median quintile.
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pause distribution, but these cannot be assessed by our
current GWAS approach.
In our sample of  3500 cases, we found no evidence for
novel genetic associations with EM that reached genome-wide
signiﬁcance thresholds. We did, however, ﬁnd genome-wide
signiﬁcant associations with four loci previously identiﬁed in
the normal menopause age QT GWAS (15). Our study was,
therefore, powered to detect associations with ORs of 1.17–
1.59, depending on the minor allele frequency. There was,
however, considerable overlap between the samples used in
the normal menopause QT GWAS and the current EM
GWAS, which may have increased our chances of detecting
such signals due to the winner’s curse phenomenon. Despite
following up two borderline signals in replication cohorts, we
were unable to detect any new variants for EM. With our
sample size of  3500 cases and  13500 controls, we had
 80% power to detect ORs of 1.2 with 30% minor allele fre-
quency SNPs. We estimated that all common variants captured
by our SNP arrays account for  20% of the variance in natural
age at menopause, thus a signiﬁcant proportion of the genetic
componenttothetraitislikelytobeduetorarerorcomplexvar-
iants not captured by the SNP arrays. We did not include non-
genetic variables in our association analyses and it is possible
that that there are genetic interactions with known environmen-
talriskfactorsforEM,e.g.smoking.EMisaheterogeneoustrait
and it is possible that clinical classiﬁcation of sub-types would
increase our power to detect genetic factors associated with
the condition. We found no evidence for a distinct genetic aeti-
ology in EM cases. If there were a genetically distinct group of
individuals at the extreme end of the distribution, by choosing a
relatively broad extreme category, representing  10% of the
menopause age distribution, there may be too much overlap
with the normal range of menopause age, thus masking any dif-
ferences.Wedidnothavesufﬁcientnumberofcaseswithmeno-
pause at ages ,40 years to perform a GWAS on this category,
butwewereabletoinvestigatetheroleofknownQTmenopause
signals in this group of women representing the extreme  1%
tail of the distribution.
We tested the 17 variants identiﬁed in the ReproGen QT
GWAS of normal menopause, in cases of EM and POI. For
all 17 variants, the allele that was associated with younger
menopause age was also associated with increased risk of
EM and POI. Only four SNPs reached genome-wide levels
of signiﬁcance for EM, but all 17 for EM and 3 for POI
were below the Bonferroni-corrected P-value of ,0.0015, as-
suming 34 independent tests. There was some evidence that
the association with POI was weaker than expected for the
SNP with largest effect on normal menopause, but this
requires a formal conﬁrmation. Stolk et al. determined
common pathways for the variants associated with age at
menopause in the normal range and highlighted DNA repair/
replication, hormonal regulation and immune function as key
pathways (15). However, there was no evidence that genes
from a particular biological pathway were more important in
EM or POI. Our data support the hypothesis that EM and
POI represent the tail of the menopause distribution and thus
have overlapping polygenic aetiology, with individuals carry-
ing more age at menopause-lowering variants having
increased risk of EM and POI.
New SNPs increase discriminative power over previous four
SNPs
By combining the effect of the 17 variants in a weighted allele
score, we demonstrated a larger effect on EM risk than the
best-known non-genetic risk factor, smoking (23,24).
However, the increased OR for EM for carriers of the most
risk alleles compared with the fewest was 2.47, which is still
signiﬁcantly lower than the OR associated with having a
mother with EM, which is about six in most reported studies
(8, 20). However, the current 17 variants only explain ,5%
of the variance in menopause age and thus as more genetic
variants are discovered the discriminative power is likely to
increase. We observed a signiﬁcant improvement in discrim-
inative power for EM when the 13 most recently described
variants were added to the ﬁrst four previously published
signals (25).
In conclusion, while much of the genetic aetiology of EM is
yet to be discovered, we have demonstrated that the combined
effect of multiple genes involved in determining the age at
normal menopause plays a role. This of course does not
exclude the possibility that rarer variants with larger effects
are also involved, as these may not have been well captured
by the SNP arrays used in the GWAS. Genetic markers of
ovarian ageing are present throughout life and thus may be su-
perior to current best predictors, e.g. AMH, inhibin B and FSH
levels, which are only reliable indicators up to about 5–10
years prior to menopause. As more genetic components of
this trait are discovered, we will be able to include additional
genetic data in predictive models for menopause age, giving
women information about potential reproductive lifespan and
enabling them to make informed reproductive choices.
MATERIALS AND METHODS
GWAS for EM
EM cases were selected from studies which contributed to the
ReproGen GWAS of normal menopause (15). EM cases were
deﬁned as women who had menopause before 45 years of age,
and controls were women with age at menopause from 50 to
60 years. Age at menopause was assessed through question-
naires, as detailed in Supplementary Material, Table S1.
Women of self-reported non-European ancestry were
excluded, as were women with menopause due to hysterec-
tomy and/or bilateral ovariectomy, or chemotherapy/irradi-
ation, if validated by medical records, and women using
hormone replacement therapy before menopause. Other vari-
ables associated with age at menopause, e.g. smoking, were
not excluded. We only included studies which had .100
EM cases. There were 10 studies included in the
meta-analysis, from the ReproGen consortium, with a total
of 3493 cases and 13598 controls (Supplementary Material,
Table S7). All samples were of European ancestry. All
cohorts performed SNP array genotyping followed by imput-
ation to HapMapII, to generate a common set of  2.5
million autosomal SNPs with a minor allele frequency of
.1% (Supplementary Material, Table S7). Each individual
study performed their own quality control for imputation
quality, deviation from Hardy–Weinberg equilibrium, SNP
call rate and lambda GC correction (Supplementary Material,
1470 Human Molecular Genetics, 2013, Vol. 22, No. 7Table S7). Meta-analysis was performed using inverse vari-
ance weighting in METAL with genomic control correction.
Heterogeneity between studies was assessed using Cochrane’s
Q statistic test in METAL. Replication was carried out in four
independent cohorts, including 3412 cases and 4928 controls
(Supplementary Material, Table S1). In silico genome-wide
SNP data were available from COLAUS, while the other
three studies performed de-novo genotyping by Taqman SNP
assay.
Analysis of 17 QT menopause SNPs in EM and POI
Association statistics for the 17 SNPs previously identiﬁed to
inﬂuence normal age at menopause were extracted from the
EM data. This included the 10 EM discovery GWAS cohorts
and 3 of the 4 replication cohorts, giving a combined sample
size of 5205 EM cases and 16926 controls. Four studies had
genotype data for the 17 SNPs on more than 100 cases with
POI (ARIC, WGHS, COLAUS, NIDO), giving a total of
1108 POI cases and 7727 controls. BGS had data on a
subset of SNPs in 2121 EM and 260 POI cases and were
added to the meta-analysis for those SNPs. Meta-analyses
were carried in METAL.
Pathway analysis
We implemented two methods to assess whether particular
gene pathways were enriched in our EM GWAS data: (i)
We used a GSEA-based approach with MAGENTA (26),
where each gene in the genome is mapped to a single index
SNP with the lowest P-value within a 110 kb upstream,
40 kb downstream window. This P-value, representing a
gene score, is then corrected for confounding factors such as
gene size, SNP density and LD-related properties in a regres-
sion model. Each mapped gene in the genome is then ranked
by its adjusted gene score. At a given signiﬁcance threshold
(95th and 75th percentiles of all gene scores), the observed
number of gene scores in a given pathway, with a ranked
score above the speciﬁed threshold percentile, is calculated.
This observed statistic is then compared with 1 000 000 ran-
domly permuted pathways of identical size. This generates
an empirical GSEA P-value for each pathway. Signiﬁcance
was determined when an individual pathway reached a false
discovery rate of ,0.05 in either analysis. In total, 2580 path-
ways from Gene Ontology, PANTHER, KEGG and Ingenuity
were tested for enrichment of multiple modest associations
with EM status.
(ii) We searched for evidence of multiple-SNP signal en-
richment at the gene level using the (VEGAS algorithm
(http://gump.qimr.edu.au/VEGAS/). This method is described
in detail by Liu et al. (http://www.cell.com/AJHG/retrieve/p
ii/S0002929710003125), but brieﬂy, test statistics across a
UCSC gene region (+50 kb) are collapsed into a single stat-
istic representing the gene. The statistic is adjusted for con-
founding factors such as gene size, LD and SNP density.
The analysis was run on the full discovery meta-analysis
summary statistics, using the default settings of the online
tool. Genes reaching a P-value of ,0.001 were analysed by
GRAIL (http://www.broadinstitute.org/mpg/grail/) for literature-
based homology to the genes within the 17 known menopause
regions. A nominal GRAIL similarity P , 0.05 was chosen
to highlight genes of interest.
Expected versus observed OR
We estimated the expected OR for both EM (,46 years) and
POI (,40 years) for each of the 17 variants, based on the
coefﬁcient estimate from the QT effect size in the normal
menopause age GWAS
15. We calculated the expected ORs
for both the point estimate QT coefﬁcient and the upper and
lower 95% CIs, by using the ‘Case–Control for threshold-
selected QTs’ analysis on the Genetic Power Calculator
website (http://pngu.mgh.harvard.edu/~purcell/gpc/). Using
the proportion of variation explained by an SNP and the
allele frequency, the program generates expected allele fre-
quencies in cases and controls, where cases and controls are
deﬁned by standard deviation thresholds. We tested three
standard deviation thresholds for EM (equivalent to the 2.5,
5 and 10% tail of the menopause distribution) and three for
POI (0.05, 1 and 2.5% tails). We then tested for heterogeneity
by a Z-test of ln(observed_OR)-ln(expected_OR)/sqrt[se_squared
(observed_OR) + se_squared(expected_OR)]. The method
assumes that menopause age is normally distributed, but this
was not tested in individual studies.
Risk prediction
Two datasets independent of the ReproGen discovery studies
were used to assess the predictive impact of the 17 menopause
SNPs—NIDO and EGCUT. First, the number of EM risk
alleles carried per individual was calculated using the
‘score’ command in PLINK. Any individuals with less than
half of the genotyped SNPs missing were excluded from ana-
lysis. The same command then creates a genotypic score for
each individual, imputing any missing genotypes based on
the sample allele frequency and gives a weighting based on
SNP effect sizes from the combined EM + replication
meta-analysis (Table 1). This score was then used to calculate
the ROC curve statistics using the ‘lroc’ command in Stata.
The results were repeated using a raw risk allele sum score
from only individuals with all genotypes present. Total
sample sizes available with a genotypic risk score and pheno-
type were 691 cases and 1394 controls (NIDO) and 647 cases
and 848 controls (EGCUT). Smoking status was available in
the EGCUT samples, indicating ‘current’, ‘former’ or
‘never’ smoking based on questionnaire data. The individuals
in these datasets were additionally partitioned into quintiles
based on their genotypic risk score. ORs were calculated for
the risk of EM based on the quintile membership, relative to
the median (third) quintile. The two cohorts were combined
in this analysis, with adjustment for cohort as an additional di-
chotomous trait in the logistic regression model.
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